Acute Myeloid Leukemia
Conditions
Interventions
experimental group:Decitabine combined with Venetoclax
Sponsors
Tianjin First Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-70 years, male or female; 2. high risk AML treated by allo-HSCT and 1 month after HSCT; 3. Not relapse after transplantation; 4. ECOG physical status score 0~2 score; 5. Ability to understand and be willing to sign the informed consent form of this trial.
Exclusion criteria
Exclusion criteria: 1. Pregnant women or lactation women; 2. Patients with uncontrolled heart failure, unstable angina, arrhythmia or mental disorders; 3. Uncontrolled infection disease; 4. HIV infected patients; 5. Patients with 3 or high stage chronic renal disease; 6. Relapse of AML; 7. Poor implantation after transplantation or blood routine examination is not satisfied with WBC > 2.0*10^9/L, ANC > 0.5*10^9/L, HBG > 90g/L, PLT > 20*10^9/L; 8. ECOG performance status > 2; 9. Major organ dysfunction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete remission state of bone marrow;remission state of hematology;event-free survival;overall survival;early mortality rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| T cell subtype; | — |
Countries
China
Contacts
Public ContactMingfeng Zhao
Department of Hematology, Tianjin First Central Hospital
Outcome results
None listed